Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial - Concepedia

Concepedia

Publication | Open Access

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

DOI Full Paper Access

189

Citations

13

References

2019

Year

Sebastian Stintzing, Pratyaksha Wirapati, Heinz‐Josef Lenz, Daniel Neureiter, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges,

Annals of Oncology

References

	Year	Citations

Page 1